Medicaid Expansion Boosts Pancreatic, Gastric Cancer Survival, Thereby Reducing Disparities


States that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

A stethoscope and calculator over a medical billing statement

Medicaid expansion may improve survival in certain cancer types, recent research showed.

Medicaid expansion programs may lead to improved survival in in pancreatic and gastric cancers, reducing racial disparities that currently exist in these cancer types, according to research that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Although not all states have expanded Medicaid, the results from this study demonstrate an attainable and concrete solution that is associated with improved survival, said Dr. Naveen Manisundaram, research fellow at The University of Texas MD Anderson Cancer Center in Houston, during a presentation of the study ahead of the meeting.

Manisundaram and colleagues analyzed data from the National Cancer Database to compare death rates for patients with gastrointestinal cancers by race and by state before (2009-2013) and after Medicaid expansion (2014-2019).

“(This database) includes community hospitals as well as academic and National Cancer Institute-designated programs, and therefore represents the most comprehensive hospital database,” Manisundaram said.

Findings from the study demonstrated that states that expanded Medicaid improved survival rates for both Black and White patients with pancreatic cancer compared with states that did not expand the program. In particular, Black patients who lived in expansion states experienced an 11.8% reduction in two-year mortality rates compared with a 2.4% reduction in states without Medicaid expansion. A similar trend was shown for White patients (10.7% reduction vs. 8.6% reduction, respectively).

For patients with late-stage pancreatic cancer, living in states with Medicaid expansion improved mortality rates compared with the states without Medicaid expansion. Manisundaram noted that these significantly greater reductions in mortality in Medicaid expansion states translated to a negative difference-in-difference for Black patients with any stage or late-stage pancreatic cancer.

Results were similar for patients with colorectal cancer, but it was primarily observed in patients with stage 4 disease. Black patients with advanced colorectal cancer had a 12.6% reduction in mortality in Medicaid-expansion states compared with a 6.1% reduction in non-expanded states.

“We found that Black patients in expansion states with stage 4 disease experienced a net increase in receipt of surgery following Medicaid expansion compared to patients in non-expansion states,” Manisundaram said.

Medicaid expansion also improved survival for patients with gastric cancers. This was demonstrated by Black patients in expansion states having greater reductions in mortality compared with non-expansion states, which also led to a negative difference-in-difference.

“One possible reason for this improvement was that late-stage Black patients in expansion states experienced increases in receipt of chemotherapy following expansion,” Manisundaram said.

At the end of the presentation, session moderator Dr. Julie R. Gralow, chief medical officer and executive vice president of ASCO, commented that although there are many analyses on the impact of Medicaid expansion, the strength of this analysis was the fact that it compared rates before and after expansion.

This is not the first time that Medicaid expansion was shown to improve outcomes. Earlier this year, data was published stating that expanded access improved breast cancer outcomes as well.

“Hopefully with solid data like this, we’ll be able to provide evidence that Medicaid expansion and the result in improved access to care can really hope help overcome the inequities in access,” she said.

She added that 40 states and the District of Columbia have now expanded Medicaid, with a few more just expanding the program in 2023, though they have not gone into effect yet.

Of note, the Affordable Care Act was passed in 2010 “to improve health care access through providing insurance coverage for low-income patients,” Manisundaram said in the presentation. The law included an expansion provision to provide funding from the federal government for states participating in the program.

Previous studies have shown that expanding Medicaid has improved access to care for patients with cancer, which includes screening and receiving cancer treatments.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE